NTRA
Natera, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$399.42
+1.52%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$402.08
From 52W high−6.16%
Volume1.26M
Market cap$57.57B
P/E (TTM)—
P/S (TTM)21.3x
Div yield—
Key dataOct 19, 2026
Open
$402.08
From 52W high
−6.16%
Volume
1.26M
Market cap
$57.57B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−317.4x
P/E (TTM)
—
RSI (14)
59.3
MomentumView details →
1D Return
+1.52%
YTD Return
+76.08%
SummaryUpdated Jun 1, 2026
Natera, Inc. (NASDAQ:NTRA) is a molecular diagnostics company founded in 2003 and headquartered in Austin, Texas. Originally known as Gene Security Network, Inc., the company changed its name to Natera in 2012 and went public in 2015. Natera has evolved from a genetics-focused startup into a leading provider of genetic testing services across three primary healthcare segments: women's health, oncology, and organ health. The company develops and commercializes advanced molecular testing services that analyze DNA to provide critical medical information for patients and healthcare providers worldwide.
Similar companies
Latest newsMore news →
Natera announced that 20 abstracts featuring its technology will be presented at the 2026 ESMO Annual Congress in Madrid from October 23 to 26.22h agoPurespring Therapeutics announced that it will give two oral presentations at ASN Kidney Week 2026 in Denver from October 21 to 25, covering PS-003 preclinical data and a global Alport syndrome genetic study.5d ago